2 of 5

1. Preface 1.1. Scope of the Report 1.2. Research Methodology 1.3. Chapter Outlines

2. Executive Summary

3. Introduction 3.1. Context and Background 3.2. Historical Evolution of Gene Therapy 3.3. Classification of Gene Therapy 3.3.1. Somatic vs. Germline 3.3.2. Ex-vivo vs. In-vivo 3.4. Route of Administration 3.5. How Does Gene Therapy Work? 3.6. Advantages and Disadvantages of Gene Therapy 3.7. Ethical and Social Concerns in Gene Therapy 3.7.1. Somatic Gene Therapy 3.7.2. Germ-line Gene Therapy 3.8. Future Constraints and Challenges 3.8.1 Manufacturing 3.8.2 Reimbursement 3.8.3 Commercial Viability

4. Viral and Non-Viral Vectors 4.1. Chapter Overview 4.2. Viral Methods of Gene Transfer 4.2.1. Retroviruses 4.2.2. Lentiviruses 4.2.3. Adenoviruses 4.2.4. Adeno Associated Virus 4.2.5. Herpes Simplex Virus 4.2.6. Alphavirus 4.2.7. Vaccinia Virus 4.2.8. Simian Virus 4.3. Non-Viral Vectors 4.3.1. Naked/Plasmid Vectors 4.3.2. Biolistic Method: Gene Gun 4.3.3. Electroporation 4.3.4. Receptor Mediated Gene Delivery Methods 4.3.5. Liposomes, Lipoplexes and Polyplexes 4.3.6. Gene Activated Matrix (GAM)

5. Pipeline of Gene Therapy 5.1. Chapter Overview 5.2. Gene Therapy: Pipeline Analysis 5.3 Oncology: The Most Popular Therapeutic Area 5.4. Distribution of Gene Therapies by Phase of Development 5.5. Distribution of Gene Therapies by Type of Vector 5.6. Distribution of Gene Therapies by Type of Genes Targeted 5.7. Distribution of Gene Therapies by Type of Sponsor

6. Marketed Gene Therapies and Applications 6.1. Chapter Overview 6.2. Gendicine (SiBionoGeneTech) 6.2.1. Company and Pipeline Overview 6.2.2. History of Approval 6.2.3. Mechanism of Action and Vectors Used 6.2.4. Target Indication 6.2.5. Development Status 6.2.6. Dosage, Sales and Manufacturing 6.2.7. Patent Portfolio 6.2.8. Gendicine Sales Forecast, 2015 - 2025 6.3. Oncorine (Shanghai Sunway Biotech) 6.3.1. Company and Pipeline Overview 6.3.2. History of Approval 6.3.3. Mechanism of Action and Vectors Used 6.3.4. Target Indication 6.3.5. Development Status 6.3.6. Dosage and Sales 6.3.7. Patent Portfolio 6.3.8. Oncorine Sales Forecast, 2015 - 2025 6.4. Rexin-G (Epeius Biotechnologies) 6.4.1. Company and Pipeline Overview 6.4.2. History of Approval 6.4.3. Mechanism of Action and Vector Used 6.4.4. Target Indication 6.4.5. Development Status 6.4.6. Dosage and Manufacturing 6.4.7. Patent Portfolio 6.4.8. Rexin-G Sales Forecast, 2015 - 2025 6.5. Neovasculgen (Human Stem Cell Institute) 6.5.1. Company and Pipeline Overview 6.5.2. History of Approval 6.5.3. Mechanism of Action and Vector Used 6.5.4. Target Indication 6.5.5. Development Status 6.5.6. Dosage, Sales and Manufacturing 6.5.7. Neovasculgen Sales Forecast, 2015 - 2025 6.6. Glybera (uniQure) 6.6.1. Company and Pipeline Overview 6.6.2. History of Approval 6.6.3. Target Indication 6.6.4. Technology 6.6.5. Development Status 6.6.6. Dosage and Manufacturing 6.6.7. Collaborations 6.6.8. Glybera Sales Forecast, 2015 - 2025

7. Gene Therapy: Pipeline Products 7.1. Chapter Overview 7.2. Generx (Taxus Cardium) 7.2.1. Company and Pipeline Overview 7.2.2. History of Development 7.2.3. Target Indication 7.2.4. Technology 7.2.5. Development Status 7.2.6. Dosage and Manufacturing 7.2.7. Collaborations 7.2.8. Generx Sales Forecast, 2015 - 2025 7.3. TK (MolMedS.p.A) 7.3.1. Company and Pipeline Overview 7.3.2. History of Development 7.3.3. Target Indication 7.3.4. Technology 7.3.5. Development Status 7.3.6. Dosage and Manufacturing 7.3.7. Collaborations 7.3.8. TK Sales Forecast, 2015 - 2025 7.4. Collategene (AnGes MG) 7.4.1. Company and Pipeline Overview 7.4.2. History of Development 7.4.3. Target Indication 7.4.4. Technology 7.4.5. Development Status 7.4.6. Dosage and Manufacturing 7.4.7. Collaborations 7.4.8. Collategene Sales Forecast, 2015 - 2025 7.5. TissueGene-C (TissueGene Inc./Kolon Life Sciences) 7.5.1. Company and Pipeline Overview 7.5.2. History of Development 7.5.3. Target Indication 7.5.4. Technology 7.5.5. Development Status 7.5.6. Dosage and Manufacturing 7.5.7. Collaborations 7.5.8. TissueGene-C Sales Forecast, 2015 - 2025 7.6. SPK-RPE65 (Spark Therapeutics) 7.6.1. Company and Pipeline Overview 7.6.2. History of Development 7.6.3. Target Indication 7.6.4. Technology 7.6.5. Development Status 7.6.6. Dosage and Manufacturing 7.6.7. Collaborations 7.6.8. SPK-RPE65 Sales Forecast, 2015 - 2025 7.7. Prostvac (Bavarian Nordic) 7.7.1. Company and Pipeline Overview 7.7.2. History of Development 7.7.3. Target Indication 7.7.4. Technology 7.7.5. Development Status 7.7.6. Dosage and Manufacturing 7.7.7. Collaborations 7.7.8. Prostvac Sales Forecast, 2015 - 2025 7.8. T-VEC (Amgen) 7.8.1. Company and Pipeline Overview 7.8.2. History of Development 7.8.3. Target Indication 7.8.4. Technology 7.8.5. Development Status 7.8.6. Dosage and Manufacturing 7.8.7. Collaborations 7.8.8. T-Vec Sales Forecast, 2015 - 2025 7.9. ProstAtak (Advantagene) 7.9.1. Company and Pipeline Overview 7.9.2. History of Development 7.9.3. Target Indication 7.9.4. Technology 7.9.5. Development Status 7.9.6. Dosage and Manufacturing 7.9.7. Collaborations 7.9.8. ProstAtak Sales Forecast, 2015 - 2025 7.10. TroVax (Oxford BioMedica) 7.10.1. Company and Pipeline Overview 7.10.2. History of Development 7.10.3. Target Indication 7.10.4. Technology 7.10.5. Development Status 7.10.6. Dosage and Manufacturing 7.10.7. Collaborations 7.10.8. TroVax Sales Forecast, 2015 - 2025 7.11. Algenpantucel-L (Newlink Genetics Corporation) 7.11.1. Company and Pipeline Overview 7.11.2. History of Development 7.11.3. Target Indication 7.11.4. Technology 7.11.5. Development Status 7.11.6. Dosage and Manufacturing 7.11.7. Collaborations 7.11.8. Algenpantucel-L Sales Forecast, 2015 - 2025 7.12. ASP0113 (Vical/Astellas Pharma) 7.12.1. Company and Pipeline Overview 7.12.2. History of Development 7.12.3. Target Indication 7.12.4. Technology 7.12.5. Development Status 7.12.6. Dosage and Manufacturing 7.12.7. Collaborations 7.12.8. ASP0113 Sales Forecast, 2015 - 2025 7.13. E10A (Marsala Biotech) 7.13.1. Company and Pipeline Overview 7.13.2. History of Development 7.13.3. Target Indication 7.13.4. Technology 7.13.5. Development Status 7.13.6. Dosage and Manufacturing 7.13.7. Collaborations 7.13.8. E10A Sales Forecast, 2015 - 2025 7.14. Other Late Phase Gene Therapies 7.15. Overall Gene Therapy Market, 2015 - 2025

8. Promising Therapeutics Areas 8.1. Chapter Overview 8.2. Cancer 8.3. Neurological Disorders 8.3.1. Neurodegenerative Disorders 8.3.2. Lysosomal Storage Disorders (LSDs) 8.4. Ocular Diseases 8.5. Muscle Disorders 8.6. Blood Disorders (Anemia and Hemophilia) 8.7. Immunodeficiency Diseases

9. Gene Therapy: Additional Considerations 9.1. Chapter Overview 9.2 Venture Capital Investment in Gene Therapy 9.3. Conferences and Exhibitions on Gene Therapy 9.4. Contract Manufacturing in Gene Therapy

10. Conclusion 10.1. Move From Monogenic Diseases To Cancer 10.2. Controlled Gene Therapy for Optimised Gene Expression: Gradually Evolving 10.3. mRNA Mediated Gene Therapy: A Promising Approach to Improve Transfection Efficiency 10.4. Germline Gene Therapy: Potential yet to Unveil 10.5. A Strong Pipeline Likely To Result In A Multi-Billion Dollar Market

11. Interview Transcripts

12. Appendix 1: Tabulated Data

13. Appendix 2: List of Companies and Organisations

List of Tables: Table 3.1 Differences between Ex vivo and In vivo Gene Therapy Table 3.2 Price comparison of Marketed Gene Therapies Table 3.3 Approved ATMPs in EU Table 4.1 Features of Retrovirus Table 4.2 Features of Lentivirus Table 4.3 Features of Adenovirus Table 4.4 Features of Adeno-associated Virus Vectors Table 4.5 Features of Herpes Simplex Virus Vectors Table 5.1 Pipeline: Approved/Marketed Gene Therapies Table 5.2 Pipeline: Pre-registration/Phase III Gene Therapies Table 5.3 Pipeline: Phase II/III Gene Therapies Table 5.4 Pipeline: Phase II Gene Therapies Table 5.5 Pipeline: Phase I/II Gene Therapies Table 5.6 Pipeline: Phase I Gene Therapies Table 5.7 Pipeline: Preclinical Stage Table 5.8 Gene Therapy: University Spin-offs Table 6.1 Marketed and Approved Gene Therapies Table 6.2 Company Overview: SiBionoGeneTech Table 6.3 Gendicine: Status of Development Table 6.4 Gendicine: Patent Portfolio Table 6.5 Company Overview: Shanghai Sunway Biotech Table 6.6 H100 Series: Status of Development Table 6.7 Company Overview: Epeius Biotechnologies Table 6.8 Rexin-G: Status of Development Table 6.9 Rexin G: Patent Portfolio Table 6.10 Company Overview: Human Stem Cell Institute Table 6.11 Neovasculgen: Status of Development Table 6.12 Company Overview: uniQure Table 6.13 Glybera: Status of Development Table 7.1 Gene Therapy: Late Stage Development Products Table 7.2 Company Overview: Taxus Cardium Table 7.3 Generx: Status of Development Table 7.4 Company Overview: MolMedS.p.A. Table 7.5 TK: Status of Development Table 7.6 Company Overview: AnGes MG Table 7.7 Collategene: Status of Development Table 7.8 Company Overview: Kolon Life Science Table 7.9 TissueGene-C: Status of Development Table 7.10 Company Overview: Spark Therapeutics Table 7.11 SPK-RPE65: Status of Development Table 7.12 Company Overview: Bavarian Nordic Table 7.13 Prostvac: Status of Development Table 7.14 Company Overview: Amgen Table 7.15 T-Vec: Status of Development Table 7.16 Company Overview: Advantagene Table 7.17 ProstAtak: Status of Development Table 7.18 Company Overview: Oxford BioMedica Table 7.19 TroVax: Status of Development Table 7.20 Company Overview: NewLink Genetics Table 7.21 Algenpantucel-L: Status of Development Table 7.22 Company Overview: Vical Table 7.23 ASP0113: Status of Development Table 7.24 Company Overview: Marsala Biotech Table 7.25 E10A: Status of Development Table 7.26 Gene Therapies in Phase II/III Table 7.27 Important Highlights of Gene Therapies in Phase II/III Table 7.28 Gene Therapy: Expected Years of Launch Table 8.1 Gene Therapy for Cancer Table 8.2 Gene Therapy for Neurological Disorders Table 8.3 Classification of Lysosomal Storage Disorders Table 8.4 Gene Therapy for Lysosomal Storage Disorders Table 8.5 Gene Therapy for Ocular Disorders Table 8.6 Gene Therapy for Muscle Disorders Table 8.7 Gene Therapy for Blood Disorders Table 8.8 Gene Therapy for Immunodeficiency Diseases Table 9.1 Recent Investments in Gene Therapy Table 9.2 Gene Transfer: Conferences 2015 Table 9.3 Contract Manufactures in Gene Therapy Table 12.1 Pipeline Analysis: Distribution by Therapeutic Area Table 12.2 Pipeline Analysis: Distribution by Phase of Development Table 12.3 Pipeline Analysis: Distribution by Type Gene Delivery Methods Table 12.4 Pipeline Analysis: Distribution by the Gene Type Table 12.5 Pipeline Analysis: Distribution by Drug Developer Type Table 12.6 Gendicine: Sales Forecast 2015 - 2025, Base Scenario (USD Million Table 12.7 Gendicine: Sales Forecast 2015 - 2025, Conservative Scenario (USD Million) Table 12.8 Gendicine: Sales Forecast 2015 - 2025, Optimistic Scenario (USD Million) Table 12.9 Oncorine: Sales Forecast 2015 - 2025, Base Scenario (USD Million Table 12.10 Oncorine: Sales Forecast 2015 - 2025, Conservative Scenario (USD Million) Table 12.11 Oncorine: Sales Forecast 2015 - 2025, Optimistic Scenario (USD Million) Table 12.12 Rexin-G: Sales Forecast 2015 - 2025, Base Scenario (USD Million) Table 12.13 Rexin-G: Sales Forecast 2015 - 2025, Conservative Scenario (USD Million) Table 12.14 Rexin-G: Sales Forecast 2015 - 2025, Optimistic Scenario (USD Million) Table 12.15 Human Stem Cell Institute: Revenues (RUB 000) Table 12.16 Neovasculgen: Sales Forecast 2015 - 2025, Base Scenario (USD Million) Table 12.17 Neovasculgen: Sales Forecast 2015 - 2025, Conservative Scenario (USD Million) Table 12.18 Neovasculgen: Sales Forecast 2015 - 2025, Optimistic Scenario (USD Million) Table 12.19 Glybera: Sales Forecast 2015 - 2025, Base Scenario (USD Million) Table 12.20 Glybera: Sales Forecast 2015 - 2025, Conservative Scenario (USD Million) Table 12.21 Glybera: Sales Forecast 2015 - 2025, Optimistic Scenario (USD Million) Table 12.22 Generx: Sales Forecast 2015 - 2025, Base Scenario (USD Million) Table 12.23 Generx: Sales Forecast 2015 - 2025, Conservative Scenario (USD Million) Table 12.24 Generx: Sales Forecast 2015 - 2025, Optimistic Scenario (USD Million) Table 12.25 TK: Sales Forecast 2015 - 2025, Base Scenario (USD Million) Table 12.26 TK: Sales Forecast 2015 - 2025, Conservative Scenario (USD Million) Table 12.27 TK: Sales Forecast 2015 - 2025, Optimistic Scenario (USD Million) Table 12.28 Collategene: Sales Forecast 2015 - 2025, Base Scenario (USD Million) Table 12.29 Collategene: Sales Forecast 2015 - 2025, Conservative Scenario (USD Million) Table 12.30 Collategene: Sales Forecast 2015 - 2025, Optimistic Scenario (USD Million) Table 12.31 TissueGene-C: Sales Forecast 2015 - 2025, Base Scenario (USD Million) Table 12.32 TissueGene-C: Sales Forecast 2015 - 2025, Conservative Scenario (USD Million) Table 12.33 TissueGene-C: Sales Forecast 2015 - 2025, Optimistic Scenario (USD Million) Table 12.34 SPK-RPE65: Sales Forecast 2015 - 2025, Base Scenario (USD Million) Table 12.35 SPK-RPE65: Sales Forecast 2015 - 2025, Conservative Scenario (USD Million) Table 12.36 SPK-RPE65: Sales Forecast 2015 - 2025, Optimistic Scenario (USD Million) Table 12.37 Incidence and Mortality Rate 2012: Prostate Cancer Table 12.38 Prostvac: Sales Forecast 2015 - 2025, Base Scenario (USD Million) Table 12.39 Prostvac: Sales Forecast 2015 - 2025, Conservative Scenario (USD Million) Table 12.40 Prostvac: Sales Forecast 2015 - 2025, Optimistic Scenario (USD Million) Table 12.41 Incidence and Mortality Rate 2014: Melanoma Table 12.42 Skin Cancer: Geographical Distribution of Death Rate (Cases per 100,000 People) Table 12.43 T-Vec: Sales Forecast 2015 - 2025, Base Scenario (USD Million) Table 12.44 T-Vec: Sales Forecast 2015 - 2025, Conservative Scenario (USD Million) Table 12.45 T-Vec: Sales Forecast 2015 - 2025, Optimistic Scenario (USD Million) Table 12.46 Incidence and Mortality Rate 2012: Prostate Cancer Table 12.47 ProstAtak: Sales Forecast 2015 - 2025, Base Scenario (USD Million) Table 12.48 ProstAtak: Sales Forecast 2015 - 2025, Conservative Scenario (USD Million) Table 12.49 ProstAtak: Sales Forecast 2015 - 2025, Optimistic Scenario (USD Million) Table 12.50 Incidence and Mortality Rate 2012: Colorectal Cancer Table 12.51 TroVax: Sales Forecast 2015 - 2025, Base Scenario (USD Million) Table 12.52 TroVax: Sales Forecast 2015 - 2025, Conservative Scenario (USD Million) Table 12.53 TroVax: Sales Forecast 2015 - 2025, Optimistic Scenario (USD Million) Table 12.54 Age-Standardised Rate 2012: Pancreatic Cancer Table 12.55 Incidence and Mortality Rate 2012: Pancreatic Cancer Table 12.56 Algenpantucel-L: Sales Forecast 2015 - 2025, Base Scenario (USD Million) Table 12.57 Algenpantucel-L: Sales Forecast 2015 - 2025, Conservative Scenario (USD Million) Table 12.58 Algenpantucel-L: Sales Forecast 2015 - 2025, Optimistic Scenario (USD Million) Table 12.59 ASP0113: Sales Forecast 2015 - 2025, Base Scenario (USD Million) Table 12.60 ASP0113: Sales Forecast 2015 - 2025, Conservative Scenario (USD Million) Table 12.61 ASP0113: Sales Forecast 2015 - 2025, Optimistic Scenario (USD Million) Table 12.62 E10A: Sales Forecast 2015 - 2025, Base Scenario (USD Million) Table 12.63 E10A: Sales Forecast 2015 - 2025, Conservative Scenario (USD Million) Table 12.64 E10A: Sales Forecast 2015 - 2025, Optimistic Scenario (USD Million) Table 12.65 Overall Gene Therapy Forecast 2015-2025: Base Scenario (USD Million) Table 12.66 Overall Gene Therapy Forecast 2015-2025: Conservative Scenario (USD Million) Table 12.67 Overall Gene Therapy Forecast 2015-2025: Optimistic Scenario (USD Million) Table 12.68 Contribution of Oncology in Gene therapy market (USD Million) Table 12.69 Number of Gene Therapies in Pre-clinical/Clinical Development for Cancer: By Disease Area Table 12.70 Number of Gene Therapies in Pre-clinical/Clinical Development for Cancer: By Transfer Vectors Table 12.71 Number of Gene Therapies in Pre-clinical/Clinical Development for Neurological Disorders: By Disease Area Table 12.72 Number of Gene Therapies in Pre-clinical/Clinical Development for Neurological Disorders: By Transfer Vectors Table 12.73 Number of Gene Therapies in Pre-clinical/Clinical Development for Lysosomal Storage Disorders: By Disease Area Table 12.74 Number of Gene Therapies in Pre-clinical/Clinical Development for Lysosomal Storage Disorders: By Transfer Vectors Table 12.75 Number of Gene Therapies in Pre-clinical/Clinical Development for Ocular Disorders: By Disease Area Table 12.76 Number of Gene Therapies in Pre-clinical/Clinical Development for Ocular Disorders: By Transfer Vectors Table 12.77 Number of Gene Therapies in Pre-clinical/Clinical Development for Muscle Disorders: By Disease Area Table 12.78 Number of Gene Therapies in Pre-clinical/Clinical Development for Muscle Disorders: By Transfer Vectors Table 12.79 Number of Gene Therapies in Pre-clinical/Clinical Development for Blood Disorders: By Disease Area Table 12.80 Number of Gene Therapies in Pre-clinical/Clinical Development for Blood Disorders: By Transfer Vectors Table 12.81 Number of Gene Therapies in Pre-clinical/Clinical Development for Immunodeficiency Diseases: By Disease Area Table 12.83 Number of Gene Therapies in Pre-clinical/Clinical Development for Immunodeficiency Diseases: By Transfer Vectors Table 12.83 Gene Therapy: Type of Investments in 2013 and 2014 Table 12.84 Gene Therapy: Investments made for different Body Systems Table 12.85 Gene Therapy Conferences in 2015: Distribution by Month Table 12.86 Contract Manufacturing in Gene Therapy: By Capability Table 12.87 Contract Manufacturing in Gene Therapy: By Location Table 12.88 Gene Therapy Market (USD Million), 2017, 2021 and 2025

List of Figures: Figure 3.1 History of Evolution: Timeline Figure 3.2 Gene Transfer using Viral Vectors Figure4.1 Gene Transfer: Viral and Non-Viral Methods Figure 5.1 Pipeline Analysis: Distribution by Therapeutic Area Figure 5.2 Pipeline Analysis: Distribution by Phase of Development Figure 5.3 Pipeline Analysis: Distribution by Type of Vector Figure 5.4 Pipeline Analysis: Distribution by Target Gene Type Figure 5.5 Pipeline Analysis: Distribution by Drug Developer Type Figure 6.1 Pipeline Overview: SiBionoGeneTech Figure 6.2 Gendicine: Sales Forecast 2015 - 2025, Base Scenario (USD Million) Figure 6.3 Pipeline Overview: Shanghai Sunway Biotech Figure 6.4 Adenovirus Construct in Oncorine Figure 6.5 Oncorine: Sales Forecast 2015 - 2025, Base Scenario (USD Million) Figure 6.6 Pipeline Overview: Epeius Biotechnologies Figure 6.7 Rexin-G: Sales Forecast 2015 - 2025, Base Scenario (USD Million) Figure 6.8 Pipeline Overview: Human Stem Cell Institute Figure 6.9 Human Stem Cell Institute: Revenues (RUB000) Figure 6.10 Neovasculgen: Sales Forecast 2015 - 2025, Base Scenario (USD Million) Figure 6.11 Pipeline Overview: uniQure Figure 6.12 Glybera: Sales Forecast 2015 - 2025, Base Scenario (USD Million) Figure7.1 Pipeline Overview: TaxusCardium Figure 7.2 Generx: Sales Forecast 2015 - 2025, Base Scenario (USD Million) Figure 7.3 Pipeline Overview: MolMedS.p.A. Figure 7.4 TK: Sales Forecast 2015 - 2025, Base Scenario (USD Million) Figure 7.5 Pipeline Overview: AnGes Figure 7.6 Collategene: Sales Forecast 2015 - 2025, Base Scenario (USD Million) Figure 7.7 Pipeline Overview: Kolon Life Science Figure 7.8 TissueGene-C: Sales Forecast 2015 - 2025, Base Scenario (USD Million) Figure 7.9 Pipeline Overview: Spark Therapeutics Figure 7.10 SPK-RPE65: Sales Forecast 2015 - 2025, Base Scenario (USD Million) Figure 7.11 Pipeline Overview: Bavarian Nordic Figure 7.12 Incidence and Mortality 2012: Prostate Cancer (in 000) Figure 7.13 Prostvac: Sales Forecast 2015 - 2025, Base Scenario (USD Million) Figure 7.14 Pipeline Overview: Amgen Figure 7.15 Incidence and Mortality 2014: Melanoma (in 000) Figure 7.16 Skin Cancer: Geographical Distribution of Death Rate (Cases per 100,000 People) Figure 7.17 T-Vec: Sales Forecast 2015 - 2025, Base Scenario (USD Million) Figure 7.18 Pipeline Overview: Advantagene Figure 7.19 Incidence and Mortality 2012: Prostate Cancer (in 000) Figure 7.20 ProstAtak: Sales Forecast 2015 - 2025, Base Scenario (USD Million) Figure 7.21 Pipeline Overview: Oxford BioMedica Figure 7.22 Incidence and Mortality 2012: Colorectal Cancer (in 000) Figure 7.23 TroVax: Sales Forecast 2015 - 2025, Base Scenario (USD Million) Figure 7.24 Pipeline Overview: NewLink Genetics Figure 7.25 Age-Standardised Rate 2012: Pancreatic Cancer Figure7.26 Incidence and Mortality 2012: Pancreatic Cancer (in 000) Figure 7.27 Algenpantucel-L: Sales Forecast 2015 - 2025, Base Scenario (USD Million) Figure 7.28 Pipeline Overview: Vical Figure 7.29 ASP0113: Sales Forecast 2015 - 2025, Base Scenario (USD Million) Figure 7.30 Pipeline Overview: Marsala Biotech Figure 7.31 E10A: Sales Forecast 2015 - 2025, Base Scenario (USD Million) Figure 7.32 Overall Gene Therapy Market Outlook 2015-2025 (USD Million) Figure 7.33 Contribution of Oncology to Gene Therapy Market Figure 8.1 Number of Gene Therapies in Pre-clinical/Clinical Development for Cancer: By Disease Area Figure 8.2 Number of Gene Therapies in Pre-clinical/Clinical Development for Cancer: By Transfer Vectors Figure 8.3 Number of Gene Therapies in Pre-clinical/Clinical Development for Neurological Disorders: By Disease Area Figure 8.4 Number of Gene Therapies in Pre-clinical/Clinical Development for Neurological Disorders: By Transfer Vectors Figure 8.5 Number of Gene Therapies in Pre-clinical/Clinical Development for Lysosomal Storage Disorders: By Disease Area Figure 8.6 Number of Gene Therapies in Pre-clinical/Clinical Development for Lysosomal Storage Disorders: By Transfer Vectors Figure 8.7 Number of Gene Therapies in Pre-clinical/Clinical Development for Ocular Disorders: By Disease Area Figure 8.8 Number of Gene Therapies in Pre-clinical/Clinical Development for Ocular Disorders: By Transfer Vectors Figure 8.9 Number of Gene Therapies in Pre-clinical/Clinical Development for Muscle Disorders: By Disease Area Figure 8.10 Number of Gene Therapies in Pre-clinical/Clinical Development for Muscle Disorders: By Transfer Vectors Figure 8.11 Number of Gene Therapies in Pre-clinical/Clinical Development for Blood Disorders: By Disease Area Figure 8.12 Number of Gene Therapies in Pre-clinical/Clinical Development for Blood Disorders: By Transfer Vectors Figure 8.13 Number of Gene Therapies in Pre-clinical/Clinical Development for Immunodeficiency Diseases: By Disease Area Figure 8.14 Number of Gene Therapies in Pre-clinical/Clinical Development for Immunodeficiency Diseases: By Transfer Vectors Figure 9.1 Gene Therapy: Type of Investments in 2013 and 2014 Figure 9.2 Gene Therapy: Investments Made for Different Body Systems (USD Million) Figure 9.3 Gene Therapy Conferences in 2015: Distribution by Month Figure 9.4 Gene Transfer: Top Conference Sponsors Figure 9.5 Contract Manufacturing in Gene Therapy: By Capability Figure 9.6 Contract Manufacturing in Gene Therapy: By Location Figure 10.1 Gene Therapy Market (USD Million), 2017, 2021 and 2025

Note: Product cover images may vary from those shown

Read the original:
Gene Therapy Market, 2015 - 2025 - Research and Markets

Comments are closed.